Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Disease progression strikingly differs in research and real-world Parkinson’s populations

View ORCID ProfileBrett K. Beaulieu-Jones, Francesca Frau, Sylvie Bozzi, Karen J. Chandross, M Judith Peterschmitt, Caroline Cohen, Catherine Coulovrat, Dinesh Kumar, Mark J. Kruger, Scott L. Lipnick, Lane Fitzsimmons, Isaac S. Kohane, Clemens R. Scherzer
doi: https://doi.org/10.1101/2024.02.17.24302981
Brett K. Beaulieu-Jones
1Department of Biomedical Informatics, Harvard Medical School, Boston, MA 02115, USA
2APDA Center for Advanced Parkinson Research of Harvard Medical School and Brigham and Women’s Hospital, Boston, MA 02115, USA
3Precision Neurology Program of Brigham & Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA
4Department of Medicine, University of Chicago, Chicago, IL 60615 USA
5Aligning Science Across Parkinson’s (ASAP) Collaborative Research Network, Chevy Chase MD, 20815
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Brett K. Beaulieu-Jones
  • For correspondence: beaulieujones{at}uchicago.edu
Francesca Frau
6Sanofi R&D, Data and Data Science, Frankfurt, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sylvie Bozzi
7Sanofi Health Economics and Value Assessment, Sanofi, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karen J. Chandross
8Sanofi R&D, Bridgewater, NJ, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M Judith Peterschmitt
9Sanofi Genzyme, Clinical Development Neurology, Cambridge, MA, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Caroline Cohen
10Sanofi R&D, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Catherine Coulovrat
11Sanofi Translational Sciences, Framingham, 01701 USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dinesh Kumar
11Sanofi Translational Sciences, Framingham, 01701 USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark J. Kruger
9Sanofi Genzyme, Clinical Development Neurology, Cambridge, MA, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Scott L. Lipnick
1Department of Biomedical Informatics, Harvard Medical School, Boston, MA 02115, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lane Fitzsimmons
1Department of Biomedical Informatics, Harvard Medical School, Boston, MA 02115, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Isaac S. Kohane
1Department of Biomedical Informatics, Harvard Medical School, Boston, MA 02115, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Clemens R. Scherzer
2APDA Center for Advanced Parkinson Research of Harvard Medical School and Brigham and Women’s Hospital, Boston, MA 02115, USA
3Precision Neurology Program of Brigham & Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA
5Aligning Science Across Parkinson’s (ASAP) Collaborative Research Network, Chevy Chase MD, 20815
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Characterization of Parkinson’s disease (PD) progression using real-world evidence could guide clinical trial design and identify subpopulations. Efforts to curate research populations, the increasing availability of real-world data and recent advances in natural language processing, particularly large language models, allow for a more granular comparison of populations and the methods of data collection describing these populations than previously possible.

This study includes two research populations and two real-world data derived (RWD) populations. The research populations are the Harvard Biomarkers Study (HBS, N = 935), a longitudinal biomarkers cohort study with in-person structured study visits; and Fox Insights (N = 36,660), an online self-survey-based research study of the Michael J. Fox Foundation. Real-world cohorts are the Optum Integrated Claims-electronic health records (N = 157,475), representing wide-scale linked medical and claims data and de-identified data from Mass General Brigham (MGB, N = 22,949), an academic hospital system. Structured, de-identified electronic health records data at MGB are supplemented using natural language processing with a large language model to extract measurements of PD progression. This extraction process is manually validated for accuracy.

Motor and cognitive progression scores change more rapidly in MGB than HBS (median survival until H&Y 3: 5.6 years vs. >10, p<0.001; mini-mental state exam median decline 0.28 vs. 0.11, p<0.001; and clinically recognized cognitive decline, p=0.001). In the real-world populations, patients are diagnosed more than eleven years later (RWD mean of 72.2 vs. research mean of 60.4, p<0.001). After diagnosis, in real-world cohorts, treatment with PD medications is initiated 2.3 years later on average (95% CI: [2.1-2.4]; p<0.001).

This study provides a detailed characterization of Parkinson’s progression in diverse populations. It delineates systemic divergences in the patient populations enrolled in research settings vs. patients in the real world. These divergences are likely due to a combination of selection bias and real population differences, but exact attribution of the causes is challenging using existing data. This study emphasizes a need to utilize multiple data sources and to diligently consider potential biases when planning, choosing data sources, and performing downstream tasks and analyses.

Competing Interest Statement

FF, SB, KJC, MJP, CC, DK, CC are employees of Sanofi and may hold shares and/or stock options in the company. All authors declare no other competing financial or non-financial interests.

Funding Statement

This work was funded in part by the Sanofi iDEA Awards Initiative (BKB) as well the National Institute of Neurological Disorders and Stroke grant number (K99NS114850, R00NS114850). CRS's work is supported in part by NIH grants NINDS/NIA R01NS115144, U01NS095736, U01NS100603, the U.S. Department of Defense, and the American Parkinson Disease Association Center for Advanced Parkinson Research. The Fox Insight Study (FI) is funded by The Michael J. Fox Foundation for Parkinson's Research. This research was funded in part by Aligning Science Across Parkinson's [ASAP-000301] through the Michael J. Fox Foundation for Parkinson's Research (MJFF).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was approved by the Mass General Brigham Institutional Review Board (#2017P002452). This study received only de-identified, retrospective data from research datasets (HBS and Fox). Research dataset participants are consented for study and publication as part of the recruitment process. Real world datasets (MGB and Optum) are retrospective de-identified data and therefore individual consent is not required for publication.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Data Availability

Authors had primary access to all data sources used in this study (BKB). All data used in this study are secondary use and therefore the authors must direct those interested in using any data involved to their source:

  1. Harvard Biomarkers set is accessible through Accelerating Medicines Partnership program for Parkinson’s disease https://amp-pd.org/unified-cohorts/hbs and through https://www.bwhparkinsoncenter.org/biobank/

  2. Mass General Brigham EMR; https://rc.partners.org/about/who-we-are-risc/research-patient-data-registry

  3. Optum® Integrated Claims-EHR Data44 (https://www.optum.com/content/dam/optum3/optum/en/resources/fact-sheets/Integrated-Data-product-sheet.pdf),

  4. Fox Insight43 https://foxinsight.michaeljfox.org/

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted February 18, 2024.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Disease progression strikingly differs in research and real-world Parkinson’s populations
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Disease progression strikingly differs in research and real-world Parkinson’s populations
Brett K. Beaulieu-Jones, Francesca Frau, Sylvie Bozzi, Karen J. Chandross, M Judith Peterschmitt, Caroline Cohen, Catherine Coulovrat, Dinesh Kumar, Mark J. Kruger, Scott L. Lipnick, Lane Fitzsimmons, Isaac S. Kohane, Clemens R. Scherzer
medRxiv 2024.02.17.24302981; doi: https://doi.org/10.1101/2024.02.17.24302981
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Disease progression strikingly differs in research and real-world Parkinson’s populations
Brett K. Beaulieu-Jones, Francesca Frau, Sylvie Bozzi, Karen J. Chandross, M Judith Peterschmitt, Caroline Cohen, Catherine Coulovrat, Dinesh Kumar, Mark J. Kruger, Scott L. Lipnick, Lane Fitzsimmons, Isaac S. Kohane, Clemens R. Scherzer
medRxiv 2024.02.17.24302981; doi: https://doi.org/10.1101/2024.02.17.24302981

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Neurology
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)